Unwavering quality in PK/PD-TOX NHP studies.
Pharmacokinetic studies, pharmacodynamic studies, and toxicology studies go hand in hand when attempts at designing new drugs and compounds are made. They are also used in order to characterize drug exposure, predict dosage requirements, assess changes in dose requirements, estimate both the rate of elimination and rate of absorption, assess the relative bioavailability and bioequivalence, characterize intra- and inter-subject variability, understand concentration-effect relationships, and last but not least, establish safety margins and efficacy characteristics. What we are trying to say is that PK/PD-TOX analyses can and should be used in a plethora of studies, and that they call for unwavering quality in their design. An unwavering quality we vow to maintain in our NHP PK/PD-TOX models at PharmaLegacy. Having doubts? Ask the leading pharmaceutical companies that PharmaLegacy has kept satisfied for years now.
MODELS / SERVICES
Extensively validated preclinical models:
- Completed over 400 FDA / CFDA IND filings
- Scientific staff with an average of over 15 years of experience in pharmacology
- PK/PD, molecular pharmacology and preliminary toxicology adjacency studies
- Capacity to house over 20,000 rodents and large animals